 ChromaDex Corp. NASDAQ:CDXC announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases NIAID, a division of the National Institutes of Health NIH. This study will assess if administration of Niagen nicotinamide riboside, or NR can reduce viral burden and inflammation in mouse and hamster models of COVID-19. ChromaDexs patent-protected NR is a unique nutrient that supports cellular energy production and healthy mitochondrial function through efficient restoration of NAD levels. The study is part of the ChromaDex External Research Program CERP in which ChromaDexs NR ingredient and placebos are provided to researchers at no cost. 